Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing
Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.
Latest From Pricing Debate
Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies
No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.
Maryland 'Price Gouging' Law's Loss In Court Could Derail Similar Legislation
Generics Firms Swap Tendering For Price Cuts In Canada
ICER To Open Cost Effectiveness Models To Drug Firms During Review Process
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.
PBM Mergers: Vertical Integration Is Cool – But Don’t Overlook Horizontal Consolidation In Part D
It is hard not to get caught up in the excitement of reinventing health care deliver amid the wave of retail, PBM and insurer merger agreements and rumors. But there is an immediate impact that might be overlooked: the Medicare Part D market is going to be much more consolidated.
Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline
Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.
Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline
Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.
Remove QALYs From Orphan HTA Assessments, Says Irish Bill
An Irish private members bill aims to exempt orphan drugs from health technology appraisals based on incremental cost-effectiveness ratio thresholds and quality adjusted life years.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.